Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis

Figure 2

Intracellular tumor necrosis factor α production in whole-blood cells from healthy donors and rheumatoid arthritis patients after adalimumab treatment. Intracellular tumor necrosis factor α (iTNFα) production was analyzed on CD14+ cells in rheumatoid arthritis (RA) patients before treatment and after 2, 6 and 12 injections of adalimumab. (A) This graph shows the percentage of iTNFα+ CD14+ after lipopolysaccharide (LPS) culture in patients before and after adalimumab treatment, after methotrexate (MTX) treatment and in healthy donors (HDs). (B) This representative image of flow cytometry results shows the percentage of iTNFα+ CD14+ cells after LPS and lipoteichoic acid (LTA) culture in RA patients before and after 12 injections of adalimumab. EULAR, European League Against Rheumatism. (C) This graph shows the percentage of iTNFα+ CD14+ cells in LPS culture before and after 2, 6 and 12 injections of adalimumab into RA patients with a good to moderate EULAR-defined response. (D) This graph shows the percentage of iTNFα+ CD14+ cells in LPS culture before and after two and three injections of adalimumab into patient 7. The two lines in this figure correspond to two missed injections of adalimumab. The dashed line corresponds to the suppression of adalimumab. (E) This graph shows percentage of iTNFα+ CD14+ cells in LPS culture before and after 2, 6 and 12 injections of adalimumab into patient 11. A paired t-test was used for statistical analysis between RA patients at different time points. A t-test was used for statistical analysis between RA patients and HDs. *P < 0.05, ***P < 0.001.

Back to article page